BioCentury | Feb 8, 2020
Emerging Company Profile

Serentrix: pain relief without side effects

Serentrix is looking to revive a well-known pain target that has been largely abandoned by drug developers after antagonists against it led to side effects. Early clinical testing by Serentrix LLC has shown that the...
BioCentury | Oct 4, 2019
Company News

Icosavax’s self-assembling vaccine platform

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
BioCentury | Feb 8, 2019
Company News

Management tracks: Takeda’s Plump becomes president of R&D

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) Andrew Plump has become president of R&D, according to the pharma's website. He was Takeda's CMO and CSO since 2015. Wolfram Nothaft, former head of global clinical development at...
BioCentury | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

...USP5) Mouse studies suggest inhibiting the USP5-calcium channel voltage-dependent T type α 1H subunit (CACNA1H; Cav3.2...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Neurology

...additional models of postsurgical pain. TARGET/MARKER/PATHWAY: Calcium channel voltage-dependent T type α 1H subunit (CACNA1H; Cav3.2...
...Colo. email: slobodan.todorovic@ucdenver.edu Claire Quang University of Colorado Denver Calcium channel voltage-dependent T type alpha 1H subunit (CACNA1H) (Cav3.2) Ubiquitin...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Feb 2, 2018
Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
BioCentury | Sep 26, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Choroidal neovascularization (CNV); ophthalmic Mouse studies suggest a cell-permeable CAV1 -based fusion peptide could help treat CNV and retinal neovascularization. In choroid and retina samples from a mouse model of CNV, levels of CAV1...
BioCentury | Jun 7, 2017
Company News

Lung Therapeutics raises $14.3M series B round

Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung’s lead product LTI-01 , a single-chain urokinase plasminogen activator, is in...
Items per page:
1 - 10 of 40